中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
15期
108-109
,共2页
甘草酸二铵肠溶胶囊%慢性病毒性肝炎%临床疗效
甘草痠二銨腸溶膠囊%慢性病毒性肝炎%臨床療效
감초산이안장용효낭%만성병독성간염%림상료효
diammonium glycyrrhizinate phosphatidylcholine complex enteric - coated capsules%chronic viral hepatitis%clinical efficacy
目的：探讨甘草酸二铵肠溶胶囊治疗慢性病毒性肝炎的临床疗效。方法将收治的慢性病毒性肝炎患者100例，随机分为对照组和治疗组，各50例。对照组给予α－2b 干扰素治疗，每次3000万 U，每周3次；治疗组在对照组基础上加用甘草酸二铵肠溶胶囊150 mg，3次/日。两组疗程均为12周。结果治疗组治疗后总有效率为92.00%，显著高于对照组的80.00%（ P <0.05）；两组总胆红素、丙氨酸氨基转移酶（ALT）、天门冬酸氨基转移酶（AST）治疗后较治疗前显著降低（ P <0.05）；治疗组总胆红素、ALT 及 AST 治疗后显著低于对照组（ P <0.05），治疗组 ALT 复常率和丙型肝炎病毒(HCV)－ RNA 转阴率显著高于对照组（ P <0.05）；两组在治疗中不良反应发生情况相似，且未出现严重的不良反应，不影响治疗。结论加用甘草酸二铵肠溶胶囊治疗慢性病毒性肝炎临床疗效显著，安全、可靠，具有重要的临床研究价值，值得进一步推广。
目的：探討甘草痠二銨腸溶膠囊治療慢性病毒性肝炎的臨床療效。方法將收治的慢性病毒性肝炎患者100例，隨機分為對照組和治療組，各50例。對照組給予α－2b 榦擾素治療，每次3000萬 U，每週3次；治療組在對照組基礎上加用甘草痠二銨腸溶膠囊150 mg，3次/日。兩組療程均為12週。結果治療組治療後總有效率為92.00%，顯著高于對照組的80.00%（ P <0.05）；兩組總膽紅素、丙氨痠氨基轉移酶（ALT）、天門鼕痠氨基轉移酶（AST）治療後較治療前顯著降低（ P <0.05）；治療組總膽紅素、ALT 及 AST 治療後顯著低于對照組（ P <0.05），治療組 ALT 複常率和丙型肝炎病毒(HCV)－ RNA 轉陰率顯著高于對照組（ P <0.05）；兩組在治療中不良反應髮生情況相似，且未齣現嚴重的不良反應，不影響治療。結論加用甘草痠二銨腸溶膠囊治療慢性病毒性肝炎臨床療效顯著，安全、可靠，具有重要的臨床研究價值，值得進一步推廣。
목적：탐토감초산이안장용효낭치료만성병독성간염적림상료효。방법장수치적만성병독성간염환자100례，수궤분위대조조화치료조，각50례。대조조급여α－2b 간우소치료，매차3000만 U，매주3차；치료조재대조조기출상가용감초산이안장용효낭150 mg，3차/일。량조료정균위12주。결과치료조치료후총유효솔위92.00%，현저고우대조조적80.00%（ P <0.05）；량조총담홍소、병안산안기전이매（ALT）、천문동산안기전이매（AST）치료후교치료전현저강저（ P <0.05）；치료조총담홍소、ALT 급 AST 치료후현저저우대조조（ P <0.05），치료조 ALT 복상솔화병형간염병독(HCV)－ RNA 전음솔현저고우대조조（ P <0.05）；량조재치료중불량반응발생정황상사，차미출현엄중적불량반응，불영향치료。결론가용감초산이안장용효낭치료만성병독성간염림상료효현저，안전、가고，구유중요적림상연구개치，치득진일보추엄。
Objective To investigate the diammonium glycyrrhizinate phosphatidylcholine complex enteric - coated capsules combined α -interferon clinical efficacy of treatment of chronic viral hepatitis. Methods 100 cases of chronic viral hepatitis who received treatment in our hospital were randomly divided into two groups, each of them were 50 cases, the control group received only interferon α - 2b therapy, 30 million IU / times, three times a week. The treatment group received the diammonium glycyrrhizinate phosphatidylcholine complex enteric - coated capsules combined α - interferon treatment, 150 mg, three times / d, The treatment lasted 12 weeks. Results The overall response rate ( 92. 00% ) was significantly higher ( 80. 00% ) after treatment, and has a statistically significant difference ( P < 0. 05); compared the two groups after treatment total bilirubin, ALT, AST treatment significantly lower than before, and are statisti-cally different ( P < 0. 05); after treatment group total bilirubin, ALT, AST treatment was significantly lower than the control group, and has a statistically significant difference ( P < 0. 05 ); treatment group ALT normalization and HCV - RNA negative rate was significantly higher, and has a statistically significant difference ( P < 0. 05); similar to the control and treatment of adverse reactions occurred in the treatment of cases, and no serious adverse reactions, does not affect the treatment. Conclusion The new formulation of diammonium glycyrrhizinate phosphatidylcholine complex enteric - coated capsules combined α - interferon treatment of chronic viral hepatitis clinically significant effect, safe and reliable, has important clinical research value, worthy of further application.
